#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Mitochondrial myopathy Breast angiosarcoma Autoimmune haemolytic anaemia Retinitis pigmentosa Solitary fibrous tumour Infertility female Autologous haematopoietic stem cell transplant Adenocarcinoma pancreas Anaplastic large cell lymphoma T- and null-cell types Polymyositis Haemophilia B with anti factor IX Oesophageal adenocarcinoma Mantle cell lymphoma Propionic acidaemia More trials…

    Learn about Rare Diseases

    MELAS syndrome – Trials in Disease Brain stem glioma – Treatment Osteosarcoma – Diagnostics Haemophilia A without inhibitors – Diagnostics Mantle cell lymphoma stage II – Life with Disease Arterial tortuosity syndrome – Diagnostics Rosai-Dorfman syndrome – Basic Information Rosai-Dorfman syndrome – Diagnostics Toxic epidermal necrolysis – Life with Disease Waldenstrom’s macroglobulinaemia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Toldc Rbd1016 Octocog Alfa ASP2957 Leuprorelin MORPHINE Promethazine Hydrochloride 177Lu-Dpi-4452 Pertuzumab Sodium Oxybate Daratumumab Sacubitril Valsartan Sertindole Zofenopril Calcium Insulin Human Ict01 Pp1493 Mycophenolate Sodium Catequentinib Dihydrochloride Emtricitabine More therapies…

    Learn about Your Condition

    Mucous membrane pemphigoid Ehlers-Danlos syndrome Triple negative breast cancer Complex regional pain syndrome Desmoid tumour External cephalic version Brain neoplasm malignant Cystic fibrosis lung Sciatica Neurofibromatosis Polymyalgia rheumatica Periarthritis Menopausal symptoms Lymphoma Childhood asthma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Avelumab for Patients with Advanced or Metastatic Squamous Cell Penile Cancer After Initial Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Penile squamous cell carcinoma
    Investigated Drugs:
    • Avelumab
    France

  • Study on Napabucasin, Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer After Chemotherapy Failure

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Napabucasin
    • Gemcitabine
    • Paclitaxel
    France Spain

  • Study on the Effects of 3 vs 6 Cycles of Platinum-based Chemotherapy and Avelumab in Patients with Advanced Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Avelumab
    France Spain

  • Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Anv600
    • Pembrolizumab
    Belgium France Germany The Netherlands Spain

  • Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Lenvatinib
    France

  • Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    Belgium France Greece Poland Spain

  • Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Fluorouracil
    France

  • Study of Atezolizumab and Tiragolumab for Patients with Recurrent or Metastatic PD-L1 Positive Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    Czechia France Greece Hungary Poland Spain

  • Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Ceralasertib
    • Durvalumab
    • Infliximab
    Belgium France Germany Italy Poland Spain

  • Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Lorlatinib
    • Axitinib
    • Talazoparib
    Belgium Denmark France Hungary Italy Poland +1
Previous Page
1 … 10 11 12 13 14 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!